

# 22<sup>ND</sup> IFFPMA ASSEMBLY 2004

## BARCELONA

27-29 OCTOBER 2004 ✧ HOTEL ARTS

---

## Patients, Partnerships and the Pharmaceutical Innovation Platform

---

- ✧ The Pharmaceutical Innovation Platform
- ✧ Innovation, Competitiveness, Access and Sustainability
- ✧ Partnerships in the fight against HIV/AIDS
- ✧ Ensuring Access to Safe and Effective Medicines
- ✧ Right to Information
- ✧ Partnerships in Developing Medicines for Neglected Populations
- ✧ The Evolving Role of NGOs
- ✧ Emerging Regional Issues – Asia, Latin America, Central Eastern Europe
- ✧ Open Markets for Better Health

# BARCELONA



**IFPMA**

International Federation of Pharmaceutical  
Manufacturers Associations

IFPMA

30, rue de Saint-Jean · P.O. Box 758  
1211 Geneva 13 · Switzerland

Phone: +41 22 338 32 00 · Fax: +41 22 338 32 99  
E-mail: [admin@ifpma.org](mailto:admin@ifpma.org) · Website: [www.ifpma.org](http://www.ifpma.org)

The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) is a non-profit making non-governmental organization (NGO) representing more than 55 national industry organizations from both developed and developing countries. Member companies of the IFPMA are the major global research-based pharmaceutical and vaccine companies. At present, our industry has over 700 new medicines and vaccines in the R & D pipeline, which will be effective in combating HIV/AIDS, cancer, heart disease, and many other illnesses.

## The Host Association

*Farmaindustria*

FARMAINDUSTRIA

Serrano, 16  
28006 Madrid · Spain

Phone: +34 91 515 93 50 · Fax: +34 91 563 73 80

FARMAINDUSTRIA BARCELONA DELEGATION

Diagonal, 361, 3º  
08037 Barcelona · Spain

Phone: +34 93 207 10 12 · Fax: +34 93 207 12 58  
E-mail: [farmaindustria@farmaindustria.es](mailto:farmaindustria@farmaindustria.es)

As of 31<sup>st</sup> December 2002, FARMAINDUSTRIA's membership comprises a total of 232 pharmaceutical companies. FARMAINDUSTRIA's members, represent more than two thirds of the pharmaceutical companies operating in Spain. The pharmaceutical industry invested more than 532 million € in R & D projects in Spain last year, thus becoming the leading sector amongst the whole Spanish industry for the first time ever, surpassing sectors such as telecommunications, automobile and aerospace development.

Secretariat :

**VIAJES EL CORTE INGLÉS**

Congress Department

C/. Princesa, 47 · 4<sup>a</sup> Plta. · 28008 Madrid (Spain)

Phone: +34 91 204 26 41/00 · Fax +34 91 547 88 87

E-mail: [ifpma2004@viajeseci.es](mailto:ifpma2004@viajeseci.es)

## **Location**

---

Hotel Arts  
Marina 19-21  
08005 Barcelona  
Spain  
Telephone: +34 93 221 1000  
Fax: +34 93 221 1070  
<http://www.ritzcarlton.com/hotels/barcelona>

## **Language**

---

The working language for the Assembly is in English.

## **Registration Desk**

---

The Registration Desk will be at the “Valdés Entrance”, which is located at the second door of the Porte Cochere, at the Ground Floor. The “Valdés Entrance” is also known as the “Group Entrance”.

## **Registration Badges**

---

For Security reasons, participants are requested to wear their registration badges for all Assembly activities and social events.

IFPMA hosts will be at Barcelona International Airport, indicating the spots from which buses will be departing.

## **Shuttle Buses From/To Airport/Hotels**

---

### **Tuesday, October 26**

From 08.00 am until 02.00 am, from/to Hotels/Airport, every thirty minutes.

### **Wednesday, October 27**

From 08.00 am until 02.00 pm, from/to Hotels/Airport, every thirty minutes.

### **Friday, October 29**

From 14.00 am until 10.00 pm, from/to Hotel Arts/Airport, every thirty minutes.

## **Shuttle Buses From/To Hotels Condes and Majestic**

---

Buses will leave from the Condes and Majestic hotels every morning 45 minutes prior to the start of the first session. Buses will return to the hotels right after the end of the last session of the day.

**Taxi Barcelona :** 93 303 303 3



## Wednesday, 27 October 2004

### 1:30 pm Keynote Session

- > Chairman: **Mr. Raymond V. Gilmartin**, Chairman, President and CEO, Merck & Co., Inc., New Jersey, USA, President IFPMA 2002-2004
- > **Dr. Supachai Panitchpakdi**, Director General, World Trade Organization (WTO), Geneva, Switzerland
- > President of Farmaindustria - "Pharmaceutical Partnership for Innovation", Madrid, Spain
- > Address by the incoming President of IFPMA for the biennial 2004-2006
- > **H.E. Mr. Joan Clos I Matheu**, Mayor of Barcelona
- > **The Honorable Pasqual Maragall I Mira**, President of Cataluña

*Audience participation*

### 2:30 pm The Pharmaceutical Innovation Platform

*New medicines, vaccines and other medical tools have revolutionized medical practice in the past century, leading to incredible health improvements, as well as profound social and economic changes globally. The demographic and epidemiological evolution necessitates on-going efforts to develop new and improved medicines that could better serve the health needs of patients. Progress in medicines is largely generated by the research-based pharmaceutical companies that have accumulated the unique skills, capacities and expertise needed to successfully conduct the complex, lengthy and costly process of pharmaceutical R&D. However, public policies and regulations largely determine the performance of these companies and thus directly influence the pace of medicines innovation. This session features a new report from IFPMA – 'Pharmaceutical Innovation Platform: Sustaining Better Health for Patients Worldwide' which describes the complex environment enabling pharmaceutical innovation.*

- > **Dr. Harvey E. Bale, Jr.**, Director General, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland

*Audience participation*

### 3:00 pm Innovation, Competitiveness, Access and Sustainability

*Preserving the innovation capacity of the pharmaceutical industry should be an important consideration for national authorities responsible for designing public health policies. Innovation in medicines provides patients with medical solutions adapted to their evolving health needs which enable a more efficient and efficacious allocation of resources by governments and health insurers. Achieving an optimal equilibrium between health and industry policy presents an important challenge that can be best faced through an open and constructive dialogue between government and industry policy makers. This session presents the policy framework in Spain, advocating for better understanding of the value of innovation in medicines as well as the underlying government policies and regulations that determine this innovation.*

- > Moderator: **Mr. Humberto Arnés Corellano**, Director General, Farmaindustria, Madrid, Spain
- > **Prof. Trevor Jones**, Member of the WHO Commission on Intellectual Property Rights and International Health (CIPRH) and former Director General of the Association of the British Pharmaceutical Industry (ABPI)
- > **Ms Marina Geli**, Councillor, Health Policy, Cataluña Government
- > **Prof. Mr. Carlos Martínez-Alonso**, President – Superior Council of Scientific Research
- > **Mr. Francisco González Robatto**, President, Spanish Association Against Cancer
- > **Dr. Antonio Esteve**, Member of Executive Committee of Esteve Group

*Audience participation*

### 4:15 pm Break

#### 4:45 pm Partnerships in the fight against HIV/AIDS

*HIV/AIDS represents an unprecedented health, social and economic burden. Combating this terrible disease must cover various grounds such as education, training, prevention, counseling, treatment and care, and requires combined efforts of various actors to succeed. The fight against HIV/AIDS requires the coordination of all actors, including patient organizations, health care professionals, local communities, civil society organizations, governments, UN agencies, and pharmaceutical companies. These collaborative efforts spread over all critical aspects of the HIV/AIDS pandemic and represent a crucial contribution to the global strategy to address this enormous health challenge. This session is an opportunity to share experiences from various partnerships fighting HIV/AIDS.*

- > Moderator: **Dr. Jeffrey L. Sturchio**, Vice President, External Affairs, Human Health – Europe, Middle East & Africa, Merck & Co., Inc., New Jersey, USA
- > **Dr. Jack Chow**, Assistant Director General for HIV/AIDS, World Health Organization (WHO), Geneva, Switzerland
- > **Mr. Donald de Korte**, Director, HIV/AIDS Service, Merck Sharp & Dohme, Paris, France
- > **Mr. William Babumba**, Capacity Building Officer, Community Health and Information Network (CHAIN), London, United Kingdom
- > **Mrs. Odile Frank**, Senior Research and Policy Adviser, Head, Research and Policy Unit, ILO Global Programme on HIV/AIDS and the World of Work, International Labour Organization

*Audience participation*

#### 6:00 pm End of Working Sessions

#### 7:30 pm Welcome Reception sponsored by IMS Health

*Gran Teatre del Liceu – Saló Espejos and Foyer Hall  
La Rambla 51-59, Barcelona*

*Shuttle bus will be departing from the main entrance of Hotel Arts and Hotel Condes at 07.15 pm  
Shuttle bus will be departing from Gran Teatre del Liceu at 10.00 pm to Hotel Arts and Hotel Majestic*



Thursday, 28 October 2004

**9:00 am Ensuring Access to Safe and Effective Medicines**

*Pharmaceutical products are subject to stringent control in terms of their quality and efficacy in order to assure that patients are not exposed to potentially hazardous and harmful substances. Unfortunately, substandard and counterfeit medicines are increasingly found in official distribution channels, both in developed and developing countries. These ineffective and often unsafe products represent a serious public health threat on the global scale. This session elaborates the need for a joint collaborative effort of different stakeholders to effectively address this growing problem.*

- > Moderator: **Dr. Roger L. Williams**, Executive Vice President and CEO, US Pharmacopoeia (USP), Rockville, MD, USA
- > **Mrs. Joy Phumaphi**, Member of the Commission on HIV/AIDS and Governance in Africa
- > **Mrs. Judith Oulton**, CEO, International Council of Nurse (ICN), Geneva, Switzerland
- > **Dr. Ibrahim Ndoye**, Executive Secretary, National AIDS Council of Senegal, Dakar, Senegal
- > **Dr. Albert I. Wertheimer**, Director, Center for Pharmaceutical Health Services Research, School of Pharmacy, Temple University, Philadelphia, USA
- > **Mr. Thomas Kubic**, Executive Director, Pharmaceutical Security Institute (PSI), Virginia, USA

*Audience participation*

**10:30 am Break**

**11:00 am Right to Information**

*The galloping evolution of communication technologies has had a phenomenal impact on access to knowledge and information worldwide, improving people's overall skills and capacities. This important benefit of the global information society has so far failed to fully materialize in the area of health. In most countries, patients still lack adequate access to valid health information, particularly regarding existing prevention and treatment options. Consequently, the level of their health literacy is far from optimal, which works to the disadvantage of patients, physicians and healthcare systems overall. This session focuses on the critical role of adequate health information in improving health status of patients and the functioning of healthcare systems in general.*

- > Moderator: **Mrs. Gabriella Stern**, Senior Editor EMEA, Dow Jones Newswires, London, United Kingdom
- > **Dr. Albert J. Jovell**, Director General, Fundació Biblioteca Josep Laporte, Barcelona, Spain
- > **Mrs. Mary G. Baker**, President, European Federation of Neurological Associations (EFNA), United Kingdom
- > **Mr. Giovanni Moro**, Programme Advisor, Active Citizenship Network, Rome, Italy
- > **Mr. David Lansky**, Foundation for Accountability, USA

*Audience participation*

**12:30 pm End of Morning Sessions**

**12:45 pm Lunch sponsored by Merck & Co., Inc.**

*Gran Saló Gaudí 3*

Keynotes: > **Prof. Richard Feachem**, Executive Director, The Global Fund to Fight AIDS, TB and Malaria, Geneva, Switzerland

## 2:30 pm Partnerships in Developing Medicines for Neglected Populations

*The health needs of poor populations present a particular challenge for the international health community. Many diseases affecting these populations are almost exclusively prevalent in developing countries that lack necessary resources, infrastructure and stability to establish proper healthcare systems and ensure access to even most basic medical interventions. The development of new drugs for some of these diseases consequently requires contributions and support of various stakeholders, including public research institutions, governments, international organizations, foundations, civil society organizations and the pharmaceutical industry. This session features several existing initiatives established to develop needed drugs for poor populations based on public-private collaboration. It examines the challenges and lessons learnt and explores the need for further collaborative efforts to improve the chances for new drugs for poor patients in need.*

- > Moderator: **Dr. Anarfi Asamoah-Baah**, Assistant Director General, Communicable Diseases, CDS Cluster, World Health Organization (WHO), Geneva, Switzerland
- > **Dr. Maria C. Freire**, CEO, Global Alliance for TB Drug Development, New York, USA
- > **Dr. Yves Champey**, President, Drugs for Neglected Diseases Initiative (DNDi), Paris, France
- > **Dr. Robert G. Ridley**, Director, Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland

*Audience participation*

## 4:00 pm Break

## 4:30 pm The Evolving Role of NGOs

*The international health community has seen some important changes over the last two decades that can be broadly characterized by the growing proliferation of players. Most importantly, the emergence of diverse forms of organization such as non-governmental organizations and multi-stakeholder partnerships have influenced the way in which health problems are addressed today. Mobilizing different stakeholders and working closely with patients and local communities, these organizations have managed to apply novel approaches yielding promising results both at the policy and at the health care provision levels. Consequently, they have become key contributors to the global health efforts and debates. This session discusses the growing importance of these different organizations as legitimate public health players.*

- > Moderator: **Dr. Bjorn Thylefors**, Director, Mectizan Donation Program, USA
- > **Mr. Richard Burzynski**, Executive Director, International Council of AIDS Service Organizations (ICASO), Toronto, Canada
- > **Mr. Yann Le Cam**, Chief Executive Officer, European Organization for Rare Diseases (EURORDIS), Paris, France
- > **Mr. James B. Russo**, Executive Director, The Partnership for Quality Medical Donations, Philadelphia, USA
- > **Dr. Carol C. Adelman**, Director, Center for Science in Public Policy, Hudson Institute, Washington DC, USA

*Audience participation*

## 6:00 pm End of Working Sessions

## 07:30 pm Dinner sponsored by Farmaindustria

*Llotja de Barcelona – Dinner Hall  
Paseo de Isabel II, s/n, Barcelona*

- > Introduction by **Mr. Raymond V. Gilmartin**, Chairman, President and CEO, Merck & Co. Inc., New Jersey, USA
- > **Ms. Elena Salgado**, Minister of Health – “Research and innovation, a key contribution to public and social objectives”, Madrid, Spain
- > Address by **Mr. José Montilla Aguilera**, Minister of Industry, Tourism and Trade, Spain

*Shuttle bus will be departing from the main entrance of Hotel Arts and Hotel Condes at 07.00 pm  
Shuttle bus will be departing from Llotja de Barcelona at 09.30 pm and 10.00 pm to Hotel Arts and Hotel Majestic*



Friday, 29 October 2004

**9:00 am Emerging Regional Issues - Asia, Latin America, Central Eastern Europe**

*Looking into the future of the pharmaceutical industry, important attention is given to the major emerging and developing countries, as both future growth markets and potential contributors to the global R&D endeavors. The implementation of the TRIPS Agreement has already initiated important changes in countries such as India and China where generic companies increasingly view the need for R&D investments as the business development strategy to pursue in the future. However, such positive signs are too often overshadowed by negative developments that occur on the level of government policies affecting the pharmaceutical industry. Such policies drastically impact the basic operating environment of the industry and can impede both its growth and innovation capacities. However, constructive policies can also promote investment by the industry in developing country markets. This session reviews different new trends that emerge in major developing and emerging markets and discusses their potential implications.*

- > Chair: **Dr. Hatsuo Aoki**, President and CEO, Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan
- > **Dr. Swati Piramal**, Director, Chief Scientific Officer, Nicholas Piramal India Limited, Mumbai, India
- > **Dr. Raul G. Dejean Rodríguez**, Undersecretary of Industry, Ministry of Economy and Production, Buenos Aires, Argentina
- > **Dr. Armin Fidler**, Health Sector Manager, Europe and Central Asia Region, The World Bank, USA
- > **Mr. Peter Scheuer**, Executive Director, R&D-based Pharmaceutical Association in China, Beijing, People's Republic of China

*Audience participation*

**11:00 am Break**

**11:30 am Open Markets for Better Health**

*Efficient markets are critical to sustaining the pharmaceutical industry's investment-innovation cycle and safeguarding the continued discovery and development of new medicines and vaccines. Too often, restrictive policies tend to limit the efficient operation of these markets by imposing various cost containment measures targeting pharmaceutical prices alone, without considering the unintended consequences for maintaining an enabling environment for innovation. Increasing government interventions and a lack of flexibility in the way pharmaceutical markets operate in major countries have already resulted in a deteriorating investment climate and increased risk of further impediments to needed pharmaceutical innovation. This session presents the arguments in favor of open and efficient markets as a major determinant of the pharmaceutical industry's competitiveness and its ability to remain innovative.*

- > Chair: **Mr. Raymond V. Gilmartin**, Chairman, President and CEO, Merck & Co. Inc., New Jersey, USA
- > Prof. **Fabio Pammolli**, University of Florence and CERM, Italy. Member of the WHO Commission on Intellectual Property Rights and International Health (CIPRH)
- > **Mr. David Ridley**, Duke University, Durham, USA
- > **Mr. James K. Glassman**, Host, Tech Central Station and Syndicated Columnist, USA

*Audience participation*

**12:30 pm Closing remarks by Mr. Raymond V. Gilmartin, Chairman, President and CEO, Merck & Co., Inc.**

**1:00 pm Lunch sponsored by Novartis**

*Gran Saló Gaudí 3*





---

# Speakers

---





## Carol C. Adelman

Dr. Carol Adelman is currently a senior fellow at the Hudson Institute where she lectures and writes on global healthcare issues, foreign aid, and international development. Dr. Adelman was a career foreign service officer with the U.S. Agency for International Development (USAID), living and working in Africa and assisting governments in Latin America and Asia. Dr. Adelman served as an Assistant Administrator at USAID, in charge of all agency programs in Asia, the Middle East, and Central and Eastern Europe. She is Vice Chairman of the Atlantic Council, a member of the Council on Foreign Relations, and is a frequent participant in foreign affairs and global development seminars and media events. Author of many articles, Dr. Adelman has published in *Foreign Affairs*, *Lancet*, *the Wall Street Journal*, *American Outlook*, *Christian Science Monitor*, and *Policy Review*. Dr. Adelman received her Doctorate and Masters in Public Health from Johns Hopkins University. She also holds a Masters in Foreign Service from Georgetown University and completed her undergraduate degree at the University of Colorado and the University of Bonn, Germany.

## Hatsuo Aoki

Dr. Hatsuo Aoki is the President and CEO of Fujisawa Pharmaceutical Co., Ltd. He is in current position since June 1999. He experienced the Chairman and CEO of Fujisawa's US subsidiary from 1993 through 1995 and took the office of President of New York Pharma Forum for one year while he was in the US. He has a scientific background with a doctorate in agricultural chemistry from the University of Tokyo and deeply involved in the research and development of tacrolimus, the Fujisawa's breakthrough immunosuppressant. Tacrolimus is currently available as Prograf, an immunosuppressant for organ rejection in organ transplant in almost 70 countries and as Protopic for the treatment of atopic dermatitis in 30 countries worldwide.

## Humberto Arnés Corellano

Mr. Arnés Corellano holds a Degree in Industrial Engineering and graduated from the Technical High School of Industrial Engineers in Barcelona in 1975. Shortly after qualifying, Mr. Arnés started his professional career working for the Ministry of Industry and Energy. Mr. Arnés has held several prestigious positions in his career to-date. He was a Director for the Pharmaceutical Industries, a Director of a Biotech and Chemical technologies Company, Director General of the Industrial Technological Development Centre (CDTI) and Director General of the Institute of Regional Promotions, Principality of Asturias (IFR). Since 2001 he holds the position of Director General of Farmaindustria (National Association of Pharmaceutical Industrial Companies).

## Anarfi Asamoah Baah

Dr. Anarfi Asamoah-Baah, from Ghana, is the Executive Director for Health Technology and Pharmaceuticals at the World Health Organization. He has been working in WHO since 1998 when he was first appointed as a senior policy advisor to the Director-General. In July 2000 he was appointed the Executive Director, External Relations and Governing Bodies of WHO. Before joining WHO, Dr. Asamoah-Baah was the Director of Medical Services for Ghana. Initially trained as a doctor with special interest in paediatrics, he started his career as a physician in charge of a small clinic in a rural province of Ghana where he developed interest in public health. Dr. Asamoah-Baah obtained post-graduate qualifications in community health, health planning, health economics and policy analysis during his studies in the UK and the US.

## William Babumba

William Babumba is the current chair and founder member of Community Health and Information Network (CHAIN) and a member of the European AIDS Treatment Group (EATG). William is a trained Laboratory haematologist by profession and has worked in a number of organisations both in the UK and in Africa. CHAIN is an international project, which lobbies for increased access to ARVs, drugs for opportunistic infections and adequate treatment education for people living with HIV/AIDS in developing countries. CHAIN's current focus is in the Great Lakes Region where it is running a capacity building programme aimed at building strong institutions of People Living With HIV/AIDS.

## Mary G. Baker

Mary G. Baker, MBE, is President of the European Federation of Neurological Associations, the European Parkinson's Disease Association, Vice President of the European Brain Council, Consultant to the World Health Organisation (WHO) and Chair of the Working Group on Parkinson's Disease, formed by the WHO in May 1997. She is Director at Large for the World Stroke Association, patient editor of the BMJ, member of the ABPI Code of Practice and has received an Honorary Doctorate from the University of Surrey in recognition of her work within the world of Parkinson's disease. Mary has also received numerous awards in recognition of her work in the field of Neurology, and PD in particular, including the European Woman of Achievement Award 2000, and the Human Communication International Award 2001.



## Harvey E. Bale

Dr. Harvey E. Bale, Jr. is the Director-General of the International Federation of Pharmaceutical Manufacturers Associations, IFPMA. Previously he was Senior Vice President for International Affairs with the Pharmaceutical Research and Manufacturers of America. Prior to that he was International Manager at Hewlett-Packard. He also served 12 years in the Office of the U.S. Trade Representative. In 1980 he was on special White House assignment to the Middle East Camp David negotiations. In 1986 he received the Distinguished Service Award from President of the United States Ronald Reagan. In 1996-1997 he taught a post-graduate course on intellectual property and technology strategy at Georgetown University. Dr. Bale received a Ph.D. in economics from University of Maryland and a B.A. from Temple University.

## Richard Burzynski

Richard Burzynski is a Canadian AIDS activist who has worked in the AIDS field for over 20 years at the local, national and international levels in the areas of advocacy and policy development. Currently, he is the Executive Director of the International Council of AIDS Service Organizations (ICASO), an organization he co-founded with other leading AIDS activists over ten years ago. Through ICASO, Richard has been an advocate for building the capacity of community-based AIDS service organizations especially in the developing world, and has worked to promote their agendas with donors, governments, multi-lateral agencies, the private sector, and the media. A frequent speaker and moderator, he serves as a principal co-organizer of the biennial international AIDS conferences. Richard helped shape the architecture of the Global Fund to Fight AIDS, TB and Malaria, and he currently serves as the Communication Focal Point of the Developed Country NGO delegation. Richard is a frequent advisor to UNAIDS.

## Yves Champey

Yves Champey is a physician with over 40 years experience in the pharmaceutical industry. He started as Medical and Scientific Director. He has worked with Miles, Pfizer and Rhone Poulenc Santé, and was Senior Vice President, International Drug Development, at Rhone Poulenc, from 1995 to 1997. Yves is a founder of ITEEC and an associate consultant providing counselling in drug research and development. He is an Advisor to the Director General of Evry Genopole – a French national project for the development of biotechnology activities, and the CEO of Genopole Day One – a private seed fund in France. In addition, Yves is a former member of Rhône-Poulenc Pharma R&D Board of Directors; has been the Secretary General and later the President of the French Association of Pharmaceutical Physicians; a Founder and the President of the Rhône-Poulenc Rorer Foundation; and a member of the Inter-Ministerial Mission on Public Research and Drug Innovation Research established by the Ministry of Research and the Ministry of Economy and Finance in France. He is one of the very early proponents of DNDi and has coordinated its creation.

## Jack C. Chow

Dr. Jack C. Chow is the Assistant Director-General of the World Health Organization for HIV/AIDS, Tuberculosis, and Malaria. Prior to joining WHO, Dr Chow held the rank of ambassador as the Special Representative of the U.S. Secretary of State for Global HIV/AIDS and as the Deputy Assistant Secretary of State for Health and Science. Dr Chow previously served in senior positions at the State Department, Department of Health and Human Services, House and Senate Appropriations Committees, and the White House Office of Science and Technology Policy. He was also a management consultant with McKinsey & Company. Dr Chow earned his M.D. from University of California at San Francisco and trained at Stanford University Hospital. His other degrees are from Harvard University's Kennedy School of Government (M.P.A), University of Chicago (M.B.A.), University of California at Berkeley (M.S.), and University of Pennsylvania (B.A.).

## Donald de Korte

Donald de Korte is heading the Expanded Access Programs of Merck & Co., Inc. in Europe, Middle East, and Africa, supporting governments, development partners, and the private sector in up-scaling the response to the HIV epidemic. In 2000, Donald established the African comprehensive HIV/AIDS Partnerships (ACHAP), a collaborative effort between the Bill & Melinda Gates Foundation, Merck & Co., Inc., the Merck Company Foundation, and the Government of Botswana. ACHAP is a unique public-private partnership concentrating on the development and implementation of a national comprehensive HIV/AIDS Strategy in Botswana, a country with the highest recorded HIV prevalence.

Donald is of Dutch nationality, and holds a Medical Doctor and Bachelor of Science degree (pharmacology) from the University of Amsterdam, in addition to a Bachelor degree from the Dutch Institute of Marketing.

## Raul Dejean Rodríguez

Dr. Raul Dejean Rodríguez was born in Buenos Aires, Argentina. He is a lawyer, specialized in International Economical Affairs and Foreign Trade. He is a member of the Argentine Foreign Service and is currently holding a post of the National Director of Imports, Undersecretary of Industry in the Ministry of Economy of Argentina. Throughout his career, Dr. Dejean Rodríguez has represented Argentina on diplomatic missions in Rome, Barcelona and Madrid. He has an extensive experience as a government official, having worked for both the Ministry of Foreign Affairs and the Ministry of Economy for many years.



## Antonio Esteve

Dr. Antonio Esteve is a member of the Executive Committee and the Director of Scientific and Commercial Operations at ESTEVE Group. He is also a Member of the Advisory Board for R&D of the Spanish Ministry of Science and Technology and the President of CTBT (Centre de Transfussió i Banc de Teixits). In 1997 he was elected a Member of the Royal Academy of Pharmacy of Catalonia. He holds a degree in pharmacy and PhD in pharmaceutical science.

## Richard G.A. Feachem

Prof. Richard G.A. Feachem, CBE is the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to this, he was Professor of International Health at the University of California, San Francisco and Berkeley. Professor Feachem has worked in international health and development for 30 years and has published extensively on public health and health policy. In 1995 he was awarded a CBE for services to international health by Her Majesty Queen Elizabeth II. In 2002 he was elected to membership of the Institute of Medicine.

## Armin Fidler

Dr. Armin Fidler is the Health Sector Manager for Europe and Central Asia at the World Bank and represents this region on the Bank's Sector Board for Health, Nutrition and Population. Dr. Fidler received his MD from the University of Innsbruck, Austria, in 1984, a Diploma in Tropical Medicine and Hygiene from the Bernhard Nocht Institute at the University of Hamburg, and a MPH in 1989 and an SM in 1990 from the Harvard School of Public Health. In addition, Dr. Fidler is an adjunct faculty at the George Washington University School of Public Health in Washington, D.C., and serves on the board of the Open Health Institute in Moscow, a non-governmental organization. Prior to joining the World Bank, Dr. Fidler worked as sub-regional advisor for the World Health Organization (PAHO/WHO) in Mexico and Central America and was admitted to the Epidemic Intelligence Service Program at CDC in Atlanta, Georgia.

## Odile Frank

Dr. Odile Frank is a Senior Technical Specialist and the Head of Research and Policy Unit of the International Labour Office (ILO). Her previous positions included the chief of Social Integration Branch, Division of Social Policy and Development, in the United Nations office in New York; a Statistician and Social Scientist at the World Health Organization (WHO), Geneva; as Associate in the Population Council, New York; an Administrator, at the Organisation for Economic Cooperation and Development (OECD), Paris; as well as an Independent Consultant, UNAIDS, Geneva. Dr. Frank was the principal author and coordinator of the ILO publication, *HIV/AIDS and Work: Global estimates, impact and response* published in 2004. She holds a B.Sc in psychology and economics from London University, and M.Sc and D.Sc. in population studies from Harvard University School of Public Health.

## Maria C. Freire

Dr. Maria C. Freire is the President and Chief Executive Officer of the Global Alliance for TB Drug Development, a position she has held since 2001. An internationally recognized expert in technology commercialization, Dr. Freire was appointed in February 2004 to the World Health Organization's newly formed Commission on Intellectual Property Rights, Innovation and Public Health (CIPRH). From 1995 to 2001, Dr. Freire directed the Office of Technology Transfer, U.S. National Institutes of Health (NIH), where she was responsible for the central development and implementation of technology transfer policies and procedures for the Department of Health and Human Services, and for the patenting and licensing activities for the NIH and the Food and Drug Administration. Prior to that, Dr. Freire established and headed the Office of Technology Development at the University of Maryland at Baltimore and the University of Maryland Baltimore County. Born in Lima, Peru, Dr. Freire trained at the Universidad Peruana Cayetano Heredia in Lima. She obtained her Ph.D. in Biophysics from the University of Virginia and completed post-graduate work in immunology and virology at the University of Virginia and the University of Tennessee, respectively.

## Marina Geli

Dr. Marina Geli is the Counsellor, Health Policy in the Catalanian Government. She holds a degree in Medicine from the Barcelona University. She practised as a physician in Josep Trueta Hospital, Girona, from 1981 till 1990. She is a specialist in infectious diseases, AIDS, community prevention among others. Dr. Geli is a funding member of several organisations related to AIDS patients's care. She has been a member of the Catalanian Parliament since 1995, and a spokesperson for Social Wellbeing of the Social Policy Committee.

## Raymond V. Gilmartin

Raymond V. Gilmartin joined Merck & Co., Inc. in June 1994 as president and chief executive officer. He was named to the additional post of chairman of the board in November 1994. Prior to joining Merck, Mr. Gilmartin was chairman, president and chief executive officer of Becton Dickinson and Company. Mr. Gilmartin serves on the boards of directors of General Mills, Inc. and the Microsoft Corporation. An active participant in health industry affairs, Mr. Gilmartin is the president of the International Federation of Pharmaceutical Manufacturers Associations. Mr. Gilmartin also serves on the executive committee of the Pharmaceutical Research & Manufacturers of America. On February 26, 2003, Mr. Gilmartin was sworn in by President George W. Bush as a member of the President's Export Council, and he also serves as a member of the Trans Atlantic Business Dialogue and the Trade and Poverty Forum.



## James K. Glassman

James K. Glassman is host of TechCentralStation.com, a public affairs website that concentrates on matters of technology and a public policy resident fellow at the American Enterprise Institute, a Washington public policy think tank, where he specializes in issues involving economics, technology and financial markets. He is also a syndicated columnist for Scripps Howard News Service and writes a syndicated financial column, which appears on the front page of the business section of the Washington Post every Sunday and is published in other newspapers, including the New York Daily News and the International Herald Tribune. Mr. Glassman has had extensive magazine publishing and television experience in the US. His articles have appeared in The Wall Street Journal, Reader's Digest, Forbes, the New York Times, the Los Angeles Times, and others. Mr. Glassman has given frequent congressional testimony, recently on subjects as varied as telecommunications policy, Securities and Exchange Commission regulations, Social Security reform, and personal investing. He is a graduate of Harvard University, where he was managing editor of the university daily, The Crimson.

## Trevor Jones

Prof. Trevor Jones is a Director of Allergan Inc and Senior R&D advisor to Esteve Spa. For 10 years until September 2004 he was Director General of the Association of the British Pharmaceutical Industry (ABPI). He is Deputy Chairman of Council and visiting professor at King's College, University of London and has been awarded honorary doctorates from five universities. Prof Jones is Scientific Director and Chairman of the Scientific Advisory Board of the venture capital business, Merlin Biosciences, and Chairman of the stem cell biotech company, ReNeuron. From 1987-94, he was a main board director of The Wellcome Foundation, where he was responsible for R&D including the development of AZT, Zovirax and other medicines. He is a founder member of the Geneva-based, public: private partnership, Medicines for Malaria Venture (MMV) and in 2004 was appointed to the World Health Organisation (WHO) Commission on Intellectual Property Rights and International Health (C.I.P.I.H). He was honoured by Her Majesty the Queen by the award of CBE in the 2003 New Year's Honours List.

## Albert J. Jovell

Dr. Albert J. Jovell is the Chief Executive Officer of the Josep Laporte's Library Foundation and Associate Professor of the Department of Preventive Medicine and Public Health of the School of Medicine of the University Autònoma of Barcelona. He is also director of the Observatory for Woman and Health, Webpacientes, Jaime Rotes Querol Library, and Clinical Management Library. Dr. Jovell holds an MD and a PhD in Sociology from University of Barcelona (Spain); a Master of Public Health (MPH) in Epidemiology, a Master of Science (MS) in Health Policy and Management, and a Doctor of Public Health (DPH) degrees from Harvard University (USA), and a MA degree in Political and Social Sciences from the University Autònoma of Barcelona (Spain). He is also specialist in Preventive Medicine and Public Health by Spanish Government. He was head of the Research and Academic Unit of the Catalan Agency for Health Technology Assessment (CATHA), a non-profit public agency in the Department of Health and Social Security of Catalonia, Spain.



## Thomas Kubic

Thomas Kubic is a former Federal law enforcement executive with national and international investigative experience. Since 2002, he has worked closely with a new PSI Board of Directors and the Members to insure the integrity of pharmaceuticals. Under his leadership, PSI has been completely reorganized to emphasize information sharing and private-public sector cooperation. Major advances included the development of the PSI Anti-counterfeiting Strategy with five supporting programs and the Counterfeit Incident Reporting System. Mr. Kubic represents the Institute at numerous international meetings, conferences and seminars. He has provided testimony concerning the international nature of counterfeiting and its devastating impact before senior government officials around the world. Among his varied responsibilities, he currently serves on the Interpol Intellectual Property Crime Action Group and advises the Permanent Forum against International Pharmaceutical Counterfeiting.

## David Lansky

David Lansky, PhD, has served as the president of the Foundation of Accountability (FACCT) since its inception in 1995. For more than twenty years, Lansky has been a proponent of a more responsive and accountable health care system. He is a nationally recognized expert in accountability and quality measurement and, as a result, has served as a board member or advisor to numerous health care projects and programs. Some of these include the National Quality Forum, Joint Commission on Accreditation of Healthcare Organizations, National Patient Safety Foundation, The Leapfrog Group, and President Bush's 2002 Economic Forum. Prior to FACCT, Lansky was a senior policy analyst for the Jackson Hole Group during the national health reform debate of 1993-94. He also led the Center for Outcomes Research and Education at Oregon-based Providence Health System.

## Yann Le Cam

Yann Le Cam is the CEO of the European Organisation for Rare Diseases (EURORDIS). As a patients' associations advocate, he has dedicated the past 17 years to professional and personal commitment to health and medical research nongovernmental organisations in France, Europe and the United States in the fields of cancer, HIV/AIDS and rare diseases. He served as Director General of the AIDES Fédération Nationale from 1992 to 1998. From 1995 to 1998 he served on the National Council of Not-For-Profit Organisations (CNVA). In 1998, he joined the French Neuromuscular Association (AFM), one of the largest patient organisations in Europe, well known for its actions on genomic and gene therapy. His role as a special advisor was to stimulate public health policy on rare diseases. In this capacity he founded, in February 2000, the Alliance Maladies Rares, a national umbrella organisation of over 100 patient associations representing over 900 rare diseases and over one million patients in France, and co-organised the first conference on orphan drugs in Europe in October 1996 at the French Senate. Yann helped to found EURORDIS in 1997 and contributed to the adoption of the European Regulation on Orphan Drugs in December 1999. Yann was trained at the Institut Superior de Gestion (MBA, 1984) and at the Centre de Perfectionnement des Affaires, Groupe HEC (Senior Executive MBA, 2000)



## Carlos Martinez-Alonso

Prof. Carlos Martinez-Alonso is the President and Professor of investigation of immunology and research at the Superior Council of Scientific Investigation (CSIC). He holds a degree in Chemistry from the Madrid Complutense University. He has worked in the immunology department of Puerta de Hierro Hospital, Madrid and also as an Associate Professor, Department of Immunology, University of Umea, Sweden.

## José Montilla

Mr. José Montilla is the Minister of Industry, Tourism and Commerce in the Spanish Government since April 2004, as well as a senior member of two leading socialist parties – PSC and PSOE. Prior to his nomination as the Minister, he was the President of the county council of Barcelona. Mr. Montilla graduated from economics and law and joined public administration as a member of the town council in Sant Joan Despi in 1979. In 1985 he became the president of the city council in Cornellà de Llobregat – the post that he held for 19 years.

## Giovanni Moro

Giovanni Moro is a political sociologist. He has carried out research and teaching activities in the fields of public policies, governance, citizenship and civic activism, European issues and corporate social responsibility. As an expert, he has cooperated with international and European institutions. He is now visiting professor at the Faculty of Education of the University of Roma Tre and is teaching at the post-degree course on “Citizenship and local welfare”, at the Faculty of Statistics of Rome La Sapienza University. He is the author of the first general handbook on civic participation published in Italy and has recently published a book on corporate social responsibility together with Alessandro Profumo, the CEO of the second Italian bank, UniCredit. From 1989 to 2002 he was the general secretary of Cittadinanzattiva, an Italian citizens’ movement founded in 1978. From 2001 to 2003 he directed, and is now program advisor, of the European branch of Cittadinanzattiva, Active Citizenship Network. He is the president of FONDACA, the Active Citizenship Foundation.

## Ibra Ndoye

Dr. Ibra Ndoye is the Executive Secretary of National AIDS Council of Senegal. Gynecologist by profession, he has authored and co-authored more than 100 publications on HIV/AIDS and STIs. As the Manager of the National AIDS program of Senegal from 1986 to date, Dr Ndoye has ensured a leadership in the widened epidemic answer to HIV/AIDS in Senegal and in the African region. He also serves as African Regional Director of the International Union against Sexually Transmitted Infections and the President of the African Union against Sexually Transmitted Infections (STIs).

## Judith A. Oulton

Judith A. Oulton is Chief Executive Officer (CEO) of the Geneva-based International Council of Nurses (ICN). ICN is a federation of 125 national nurses' associations representing millions of nurses worldwide. Prior to joining ICN, Oulton served for seven years as the Executive Director of the Canadian Nurses Association (CNA) and the Canadian Nurses Protective Society. She was also Chair of the Health Action Lobby (HEAL), a coalition of more than twenty Canadian health and consumer organisations. Ms Oulton was previously Director of Strategic Planning for the Department of Health and Community Services of the Province of New Brunswick, Canada. Her career has included experience: in government as Senior Nursing Consultant with major responsibility in hospital organisation and budgetary audits; in education as a professor in the Nursing Faculty, University of New Brunswick; and in nursing administration and service in a variety of clinical areas.

## Fabio Pammolli

Fabio Pammolli is a Full Professor of Economics and Management, Faculty of Economics, University of Florence. In the past, he served as a Director, I.M.T. Graduate Studies, The Sant'Anna School of Advanced Studies (1989-1991). His research interests are in the fields of: Industrial Dynamics and Market Regulation; Economics of Innovation; Economic Analysis of the Pharmaceutical Industry. Prof. Pammolli is a member of the Commission on Intellectual Property Rights, Innovation, and Public Health, World Health Organization. He is also Director at EPRIS (European Pharmaceutical Innovation and Regulation Systems), as well as Founder and Director, CERM (Magnetic Resonance Centre in Florence).

## Joy Phumaphi

Since August 2003, Joy Phumaphi is the Assistant Director-General, Family and Community Health cluster at the World Health Organization in Geneva, Switzerland. She was the Minister of Health, Botswana and the Member of Parliament for Francistown East until July 2003. Ms Phumaphi is a distinguished African American Institute Fellow and is a Commissioner in the UN Secretary General's Commission on HIV/AIDS and Governance in Africa. She is patron of the following organizations: Women's Shelter Project, Balekane Society, Botswana Widows' Association, Botswana Christian Council AIDS Intervention Programme, Supa Ngwao Museum and Motswedi Rehabilitation Centre. She also serves on the Board of Junior Achievement Botswana. Ms Phumaphi has also served as a member of the UN Reference Group on Economics (URGE) as well as a member of the UNDP Advisory Board for Africa.

## Swati Piramal

Dr. Swati Piramal is a Director of Nicholas Piramal India Ltd where she looks after Research, Intellectual Property Policy, Strategic Alliances and Communication. She is a Medical Doctor with a Master's Degree in Public Health from Harvard University, USA. She is on the Prime Minister's Governing Board for Scientific Research and the Economic and Biotechnology Councils for Rajasthan and Maharashtra. Dr. Piramal is a member of the Commission on Intellectual Property Rights, Innovation, and Public Health, World Health Organization and is actively involved in other organisations including the World Economic Forum, Confederation of Indian Industry (CII) Biotechnology and Life Sciences cell. She has been nominated one of the top 25 Most Powerful Business Women in India. She is on the board of several biotechnology, insurance and pharmaceutical companies.



## David Ridley

David Ridley, Ph.D., is an Assistant Professor of the Practice at the Fuqua School of Business at Duke University. David's research focuses on health sector business strategies, such as pricing and market entry, and the impact of government regulations on those strategies. At Duke University David has taught health economics, microeconomics, industrial organization, game theory, and pharmaceutical strategy and management. David earned his Ph.D. in Economics at Duke University in 2001.

## Robert G. Ridley

Dr. Robert G. Ridley is the Director of the TDR Programme for Research and Training on Tropical Diseases cosponsored by WHO, UNICEF, UNDP and the World Bank. Prior to being appointed Director in June, Dr Ridley was the Coordinator of Product R&D within TDR, with overall responsibility for drugs, vaccines and diagnostics. His background covers organic chemistry, biochemistry and molecular biology. Between 1980 and 1992, he held positions at the University of Malawi, McMaster University (Canada), and Edinburgh University (U.K.). He then moved to Hoffmann-La-Roche, Switzerland, as Vice Director – Infectious Diseases Drug Discovery department. In 1998, he joined TDR to manage drug discovery research. From there, he helped launch the Medicines for Malaria Venture for which he acted as Chief Executive Officer in 1999. Dr Ridley's areas of interest and experience cover issues relating to the use of drugs, their financing and provision in poor countries, as well as public sector interaction with the industry. He has published widely on malaria research.

## Jim Russo

Jim Russo has been Executive Director of the Partnership for Quality Medical Donations since its founding in 1999. PQMD's mission is to raise standards of medical donations, document their impacts and sponsor educational forums for the donations community at large. As the first signatory to the World Health Organization Guidelines on drug donations, PQMD collaborates with the World Health Organization, the World Bank and various academic institutions to study donation practices, address problems and improve standards. The PQMD Board is composed of ten leading pharmaceutical/medical equipment makers and twelve of the foremost humanitarian agencies working in over 150 nations. PQMD meetings are noted for collegiality, open sharing of ideas, and the start of joint projects involving organizations from diverse backgrounds. Russo worked at PhRMA in Washington for 18 years and 18 more in policy development at GlaxoSmithKline. He consulted for Novartis and various humanitarian agencies before being asked the lead PQMD. He holds a Bachelor of Science degree from Temple University.

## Elena Salgado Méndez

Ms Elena Salgado Méndez is the President of 11811Nueva Información Telefónica and a member of the Board of Directors of Abertis Telecom. Throughout her professional career, she has held numerous posts in the Spanish government, including the Director-General for Personnel Expenditure and Public Pensions in the Ministry of Economy and Finance, and the Secretary-General for Communications in the Ministry of Public Works, Transport and Environment. Ms Salgado Méndez has developed significant expertise in advanced technology sector, resulting from her extensive experience as a senior executive in Arthur Andersen and Lenci Consultong LC. She received her first university degree in industrial organisation from Universidad Politécnica Madrid, Masters degree in quantitative management methods from Escuela Organización Industrial as well as industrial engineer degree specialising in energy from Universidad Politécnica de Madrid.

## Peter Scheuer

Peter Scheuer is the Executive Director of R&D-based Pharmaceutical Association in China since 1999. He played a key role in establishing and participating in working groups in drug regulatory and medical affairs, price/reimbursement/bidding, intellectual property, communications, code of pharmaceutical marketing practices, etc. and in organizing government/industry roundtables and conferences: Reform of Pharmaceutical and Healthcare System (2002); Encouraging Pharmaceutical R&D in Emerging Countries, Focus on China (2003); IFPMA 4<sup>th</sup> Asian Regulatory Conference, Beijing (2004). From 1993 to 1999, Peter Scheuer was Legal Counsel to U.S./European Companies on investment and litigation matters in China, including: largest company in the world and companies ranked within the top five in pharmaceutical, IT and telecom. From 1984 to 1992, he practiced as local government attorney in U.S.

## Gabriella Stern

Gabriella Stern is Dow Jones Newswires' Senior Editor for Europe, the Middle East and Africa (EMEA). She has overall responsibility for editorial operations in the region, which includes some 220 journalists and stretches from Dublin to Dubai. Dow Jones & Company acquired the news division of vwd Vereinigte Wirtschaftsdienste GmbH in March 2004, which added another 100 journalists to Gabby's team. Gabriella has two decades of journalistic experience, including stints at the Associated Press while a student at Yale University, where she earned Bachelor's and Master's degrees.

## Jeffrey L. Sturchio

Dr. Jeffrey L. Sturchio is Vice President, External Affairs, Human Health – Europe, Middle East & Africa at Merck & Co., Inc., where he is responsible for developing, coordinating, and implementing a range of health policy and communications initiatives for the region. He has been centrally involved in Merck's participation in the UN/Industry Accelerating Access Initiative to help improve HIV/AIDS care and treatment in the developing world. He is also a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria. Dr. Sturchio was educated at Princeton (A.B., 1973) and the University of Pennsylvania (Ph.D., 1981). Before joining Merck in 1989 after a brief sojourn at AT&T, he was an academic historian. His publications include "What information do patients need about medicines? Perspectives from the pharmaceutical industry" (with S. Bonaccorso), *British Medical Journal* 327 (11 October 2003): 863-864; and "Successful public-private partnerships in global health: lessons from the MECTIZAN Donation Program," (with B. Colatrella), in *The Economics of Essential Medicines*, ed. by B. Granville (London: Royal Institute of International Affairs, 2002).

## Supachai Panitchpakdi

Born in Bangkok, Dr. Supachai received his Master's Degree in Econometrics, Development Planning and his Ph.D. in Economic Planning and Development at the Netherlands School of Economics (now known as Erasmus University) in Rotterdam. Dr. Supachai began his professional career at the Bank of Thailand in 1974, working in the Research Department, the International Finance Division and the Financial Institutions Supervision Department. In 1986, Dr. Supachai was elected a member of the Thai Parliament and was appointed Deputy Minister of Finance. In 1988, he was appointed Director and Advisor, and subsequently President, of the Thai Military Bank. In 1992, Dr. Supachai was appointed Senator and that same year he became Deputy Prime Minister entrusted with oversight of the country's economic and trade policy making. In September 1999, he was elected Director General of World Trade Organization (WTO) taking office on 1 September 2002. He has published a number of books including *Globalization and Trade in the New Millenium* (2001) and *China and WTO: Changing China Changing WTO* (2002, co-authored with Mark Clifford).



## Björn Thylefors

Dr. Björn Thylefors recently joined The Task Force for Child Survival and Development as Director of the Mectizan Donation Program. Prior to joining the Mectizan Donation Program, Dr. Thylefors was based in Geneva, Switzerland where he served as Programme Manager and Director of the World Health Organization Programme for the Prevention of Blindness. During his career with WHO he also served as Director of the WHO Department of Disability/Injury Prevention and Rehabilitation. Dr. Thylefors has a wealth of experience in the field of international health, particularly in onchocerciasis and the prevention of blindness. He received a Medical Diploma from the University of Göteborg, a Swedish Diploma in Ophthalmology, a Diploma in Epidemiology from the Nordic School of Public Health, and an Academic Doctorate in Medicine from the University of Göteborg. He has authored more than 70 scientific papers and articles.

## Daniel Vasella

Daniel Vasella, MD, is Chairman and CEO of Novartis AG. He was appointed Chairman in April 1999, having served as CEO and Head of the Group Executive Committee since the merger in 1996. His Novartis career began at Sandoz Pharma in 1988, where he assumed the position of CEO in 1994. Prior to joining Sandoz, Dr. Vasella held a number of medical positions in Switzerland. Dr. Vasella is a member of the Board of Directors of PepsiCo Inc. and of the Chairman's Council of DaimlerChrysler. He is also a member of the International Business Leaders Advisory Council for the Mayor of Shanghai and of the International Board of Governors of the Peres Center for Peace. In 2002 Dr. Vasella was awarded an honorary doctorate by the Faculty of Medicine of the University of Basel.

## Albert I. Wertheimer

Albert I. Wertheimer, PhD, MBA is Founding Director of the Center for Pharmaceutical Health Services Research (PHSR) and a tenured professor at the School of Pharmacy, Temple University, Philadelphia. Dr. Wertheimer is internationally recognized in the area of pharmacoconomics and outcomes research. He is Editor-in-Chief of the newly launched Journal of Pharmaceutical Finance, Economics and Policy and author or co-editor of 21 books, 27 chapters and more than 340 journal articles. He had served as a consultant or lecturer in 55 countries and is active in managed care and international pharmacy, serving on numerous task forces, committees and organizational advisory panels.

## Roger L. Williams

Roger L. Williams, M.D., Executive Vice President and CEO of the United States Pharmacopeia (USP) since April 2000. Dr. Williams provides strategic leadership for USP and serves as chair of the Council of Experts, USP's scientific body. Dr. Williams received his undergraduate degree at Oberlin College and his medical degree and training in internal medicine at the University of Chicago. He completed his fellowship in clinical pharmacology at the University of California, San Francisco, in 1974, where he continues as a faculty member. He joined the Food and Drug Administration in 1990 as director of the Office of Generic Drugs in the Center for Drug Evaluation and Research. He became deputy center director for pharmaceutical science in 1995, overseeing the Center's Office of New Drug Chemistry, Office of Generic Drugs, Office of Clinical Pharmacology and Biopharmaceutics, and Office of Research and Testing. Dr. Williams is a member of the medical honor societies Phi Beta Kappa and Alpha Omega Alpha, as well as various scientific organizations.



